Information
The Nanobesity product is a disruptive nanomolecule, ideal for nasal administration, specifically targeting hypothalamic areas to modulate appetite, food intake, and insulin resistance. These nanomolecules are fully protein-based, with optimal characteristics (size, zeta potential, mucoadhesion charges, biocompatibility) to reach brain cells via intranasal delivery, overcoming the limitations of current nanomedicines. The technology is cost-effective, scalable, and offers a homogeneous formulation with greater biocompatibility than other brain delivery platforms. This will be the first brain-targeted nanomedicine designed to combat obesity and diabetes, avoiding the off-target effects, toxicity, and inefficiencies associated with existing drugs.